Pathophysiological function of oxytocin secreted by neuropeptides: A mini review

Pathophysiology

Volumn 19, Issue 4, 2012, Pages 283-298

  Hashimoto, Hirofumi ^a   Uezono, Yasuhito ^b   Ueta, Yoichi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adrenomedullin family; Cholecystokinin; Hypothalamus; Neuropeptides; Paraventricular nucleus; Supraoptic nucleus

Indexed keywords

ADRENOMEDULLIN; APELIN; CHOLECYSTOKININ; KISSPEPTIN; NESFATIN 1; NEUROPEPTIDE; OXYTOCIN; OXYTOCIN RECEPTOR; PROLACTIN RELEASING FACTOR; SECRETIN; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ANXIETY; FEEDING; GENE; GENE EXPRESSION REGULATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; OXYTOCIN GENE; OXYTOCIN RECEPTOR GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; RECOGNITION; REVIEW; SODIUM APPETITE;

EID: 84868638385     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2012.07.005     Document Type: Review

References (230)

1. Dale H. On some physiological actions of ergot. The Journal of Physiology 1906, 34:163-206.
2. du Vigneaud V., Ressler C., Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. The Journal of Biological Chemistry 1953, 205:949-957.
3. du Vigneaud V., Ressler C., Swan J., Roberts C., Katsoyannis P., Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. Journal of the American Chemical Society 1953, 75:4879-4880.
4. du Vigneaud V., Ressler C., Swan J., Roberts C. The synthesis of oxytocin. Journal of the American Chemical Society 1954, 76:3115-3121.
5. Swanson L.W., Kuypers H.G.H.G. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. The Journal of Comparative Neurology 1980, 194:555-570.
6. Sofroniew M.V. Morphology of vasopressin and oxytocin neurones and their central and vascular projections. Progress in Brain Research 1983, 60:101-114.
7. Carmichael M., Humbert R., Dixen J., Palmisano G., Greenleaf W., Davidson J. Plasma oxytocin increases in the human sexual response. The Journal of Clinical Endocrinology and Metabolism 1987, 64:27-31.
8. Carmichael M., Warburton V., Dixen J., Davidson J. Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Archives of Sexual Behavior 1994, 23:59-79.
9. Russell J., Leng G. Sex, parturition and motherhood without oxytocin?. The Journal of Endocrinology 1998, 157:342-359.
10. Leckman J., Goodman W., North W., Chappell P., Price L., Pauls D., Anderson G., Riddle M., McDougle C., Barr L., et al. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology 1994, 19:723-749.
11. Stock S., Uvnas-Moberg K. Increased plasma levels of oxytocin in response to afferent electrical stimulation of the sciatic and vagal nerves and in response to touch and pinch in anaesthetized rats. Acta Physiologica Scandinavica 1988, 132:29-34.
12. Uvnäs-Moberg K., Bruzelius G., Alster P., Lundeberg T. The antinociceptive effect of non-noxious sensory stimulation is mediated partly through oxytocinergic mechanisms. Acta Physiologica Scandinavica 1993, 149:199-204.
13. Burbach P., Young L.J., Russell J. Oxytocin: synthesis, secretion and reproductive functions. Knobil and Neill's Physiology of Reproduction 2006, 3055-3127. Elsevier, Amsterdam. J.D. Neill (Ed.).
14. Sofroniew M. Projections from vasopressin, oxytocin, and neurophysin neurons to neural targets in the rat and human. The Journal of Histochemistry and Cytochemistry 1980, 28:475-478.
15. Ivell R., Furuya K., Brackmann B., Dawood Y., Khan-Dawood F. Expression of the oxytocin and vasopressin genes in human and baboon gonadal tissues. Endocrinology 1990, 127:2990-2996.
16. Ivell R., Balvers M., Rust W., Bathgate R., Einspanier A. Oxytocin and male reproductive function. Advances in Experimental Medicine and Biology 1997, 424:253-264.
17. Frayne J., Nicholson H.D. Effect of oxytocin on testosterone production by isolated rat Leydig cells is mediated via a specific oxytocin receptor. Biology of Reproduction 1995, 52:1268-1273.
18. Frayne J., Nicholson H.D. Localization of oxytocin receptors in the human and macaque monkey male reproductive tracts: evidence for a physiological role of oxytocin in the male. Molecular Human Reproduction 1998, 4:527-532.
19. Foo N.C., Carter D., Murphy D., Ivell R. Vasopressin and oxytocin gene expression in rat testis. Endocrinology 1991, 128:2118-2128.
20. Nicholson H.D., Hardy M.P. Luteinising hormone differentially regulates the secretion of testicular oxytocin and testosterone by purified rat Leydig cells in vitro. Endocrinology 1992, 130:671-677.
21. Filippi S., Vannelli G.B., Granchi S., Luconi M., Crescioli C., Mancina R., Natali A., Brocchi S., Vignozzi L., Bencini E., Noci I., Ledda F., Forti G., Maggi M. Identification, localisation and functional activity of oxytocin receptors in epididymis. Molecular and Cellular Endocrinology 2002, 193:89-100.
22. Harris G.C., Frayne J., Nicholson H.D. Epididymal oxytocin in the rat; its origin and regulation. International Journal of Andrology 1996, 19:278-286.
23. Whittington K., Assinder S., Gould M., Nicholson H. Oxytocin, oxytocin associated neurophysin and the oxytocin receptor in human prostate. Cell and Tissue Research 2004, 318:375-382.
24. Ogawa S., Kudo S., Kitsunai Y., Fukuchi S. Increase in oxytocin secretion at ejaculation in male. Clinical Endocrinology 1980, 13:95-97.
25. Carmichael M.S., Humbert R., Dixen J., Palmisano G., Greenleaf W., Davidson J.M. Plasma oxytocin increases in the human sexual response. The Journal of Clinical Endocrinology and Metabolism 1987, 64:27-31.
26. Murphy M.R., Seckl J.R., Burton S., Checkley S.A., Lightman S.L. Changes in oxytocin and vasopressin secretion during sexual activity in men. The Journal of Clinical Endocrinology and Metabolism 1987, 65:738-741.
27. Ludwig M., Leng G. Dendritic peptide release and peptide-dependent behaviours. Nature Review Neuroscience 2006, 7:126-136.
28. Castel M., Morris J. The neurophysin-containing innervation of the forebrain of the mouse. Neuroscience 1988, 24:937-966.
29. de Vries G., Buijs R. The origin of vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Research 1983, 273:307-317.
30. van Tol H., Bolwerk E., Liu B., Burbach J. Oxytocin and vasopressin gene expression in the hypothalamo-neurohypophyseal system of the rat during the estrous cycle, pregnancy, and lactation. Endocrinology 1988, 122:945-951.
31. Zingg H., Lefebvre D. Oxytocin and vasopressin gene expression during gestation and lactation. Brain Research 1988, 464:1-6.
32. Thomas A., Amico J. Sequential estrogen and progesterone (P) followed by P withdrawal increases the level of oxytocin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the male rat. Life Sciences 1996, 58:1615-1620.
33. Lefebvre D., Farookhi R., Giaid A., Neculcea J., Zingg H. Uterine oxytocin gene expression. II. Induction by exogenous steroid administration. Endocrinology 1994, 134:2562-2566.
34. Ostrowski N. Oxytocin receptor mRNA expression in rat brain: implications for behavioral integration and reproductive success. Psychoneuroendocrinology 1998, 23:989-1004.
35. Fuchs A., Periyasamy S., Alexandrova M., Soloff M. Correlation between oxytocin receptor concentration and responsiveness to oxytocin in pregnant rat myometrium: effects of ovarian steroids. Endocrinology 1983, 113:742-749.
36. Soloff M., Fernstrom M.M., Periyasamy S., Soloff S., Baldwin S., Wieder M. Regulation of oxytocin receptor concentration in rat uterine explants by estrogen and progesterone. Canadian Journal of Biochemical Cellular Biology 1983, 61:625-630.
37. Maggi M., Magini A., Fiscella A., Giannini S., Fantoni G., Toffoletti F., Massi G., Serio M. Sex steroid modulation of neurohypophysial hormone receptors in human nonpregnant myometrium. The Journal of Clinical Endocrinology and Metabolism 1992, 74:385-392.
38. Breton C., Pechoux C., Morel G., Zingg H. Oxytocin receptor messenger ribonucleic acid: characterization, regulation, and cellular localization in the rat pituitary gland. Endocrinology 1995, 136:2928-2936.
39. Larcher A., Neculcea J., Breton C., Arslan A., Rozen F., Russo C., Zingg H. Oxytocin receptor gene expression in the rat uterus during pregnancy and the estrous cycle and in response to gonadal steroid treatment. Endocrinology 1995, 136:5350-5356.
40. Pedersen C., Ascher J., Monroe Y., Prange A. Oxytocin induces maternal behavior in virgin female rats. Science 1982, 216:648-650.
41. Fahrbach S., Morrell J., Pfaff D. Possible role for endogenous oxytocin in estrogen-facilitated maternal behavior in rats. Neuroendocrinology 1985, 40:526-532.
42. Young L., Winslow J., Wang Z., Gingrich B., Guo Q., Matzuk M., Insel T. Gene targeting approaches to neuroendocrinology: oxytocin, maternal behavior, and affiliation. Hormones and Behavior 1997, 31:221-231.
43. Meddle S., Bishop V., Gkoumassi E., van Leeuwen F., Douglas A. Dynamic changes in oxytocin receptor expression and activation at parturition in the rat brain. Endocrinology 2007, 148:5095-5104.
44. Insel T. Regional changes in brain oxytocin receptors post-partum: time-course and relationship to maternal behaviour. Journal of Neuroendocrinology 1990, 2:539-545.
45. Pedersen C., Caldwell J., Walker C., Ayers G., Mason G. Oxytocin activates the postpartum onset of rat maternal behavior in the ventral tegmental and medial preoptic areas. Behavioral Neuroscience 1994, 108:1163-1171.
46. Millan M.J., Millan M.H., Członkowski A., Herz A. Vasopressin and oxytocin in the rat spinal cord: distribution and origins in comparison to [Met] enkephalin, dynorphin and related opioids and their irresponsiveness to stimuli modulating neurohypophyseal secretion. Neuroscience 1984, 13:179-187.
47. Lundeberg T., Meister B., Bjorkstrand E., Uvnas-Moberg K. Oxytocin modulates the effects of galanin in carrageenan-induced hyperalgesia in rats. Brain Research 1993, 608:181-185.
48. Puder B., Papka R. Hypothalamic paraventricular axons projecting to the female rat lumbosacral spinal cord contain oxytocin immunoreactivity. Journal of Neuroscience Research 2001, 64:53-60.
49. Xu X., Wiesenfeld-Hallin Z. Intrathecal oxytocin facilitates the spinal nociceptive flexor reflex in the rat. Neuroreport 1994, 5:750-752.
50. Yang J., Yang Y., Chen J.M., Liu W.Y., Wang C.H., Lin B.C. Central oxytocin enhances antinociception in the rat. Peptides 2007, 28:1113-1119.
51. Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. Spine 1994, 19:867-871. (Phila Pa 1976).
52. Conde's-Lara M., Maie I., Dickenson A. Oxytocin actions on afferent evoked spinal cord neuronal activities in neuropathic but not in normal rats. Brain Research 2005, 1045:124-133.
53. Lundeberg T., Uvnas-Moberg K., Agren G., Bruzelius G. Anti-nociceptive effects of oxytocin in rats and mice. Neuroscience Letters 1994, 170:153-157.
54. Gu X.L., Yu L.C. Involvement of opioid receptors in oxytocin-induced antinociception in the nucleus accumbens of rats. Journal of Pain 2007, 8:85-90.
55. Schorscher-Petcu A., Sotocinal S., Ciura S., Dupré A., Ritchie J., Sorge R.E., Crawley J.N., Hu S.B., Nishimori K., Young L.J., Tribollet E., Quirion R., Mogil J.S. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. The Journal of Neuroscience 2010, 30:8274-8284.
56. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews 2001, 81:629-683.
57. Arnaudeau S., Leprêtre N., Mironneau J. Oxytocin mobilizes calcium from a unique heparin-sensitive and thapsigargin-sensitive store in single myometrial cells from pregnant rats. Pflugers Archiv: European Journal of Physiology 1994, 428:51-59.
58. Ku C.Y., Qian A., Wen Y., Anwer K., Sanborn B.M. Oxytocin stimulates myometrial guanosine triphosphatase and phospholipase-C activities via coupling to G alpha q/11. Endocrinology 1995, 136:1509-1515.
59. Phaneuf S., Asboth G., Europe-Finner G.N., Watson S.P., Lopez Bernal A. Second messenger pathways for oxytocin and prostaglandins in human myometrium. Biochemical Society Transactions 1995, 23:21S.
60. Schöneberg T., Kostenis E., Liu J., Gudermann T., Wess J. Molecular aspects of vasopressin receptor function. Advances in Experimental Medicine and Biology 1998, 449:347-358.
61. Thibonnier M., Berti-Mattera L.N., Dulin N., Conarty D.M., Mattera R. Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Progress in Brain Research 1998, 119:147-161.
62. Birnbaumer M. Vasopressin receptors. Trends in Endocrinology and Metabolism 2000, 11:406-410.
63. Chini B., Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochemical Society Transactions 2007, 35:737-741.
64. Windle R.J., Shanks N., Lightman S.L., Ingram C.D. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 1997, 138:2829-2834.
65. Windle R.J., Wood S., Shanks N., Perks P., Conde G.L., da Costa A.P., Ingram C.D., Lightman S.L. Endocrine and behavioural responses to noise stress: comparison of virgin and lactating female rats during non-disrupted maternal activity. Journal of Neuroendocrinology 1997, 9:407-414.
66. Amico J.A., Mantella R.C., Vollmer R.R., Li X. Anxiety and stress responses in female oxytocin deficient mice. Journal of Neuroendocrinology 2004, 16:319-324.
67. Windle R.J., Gamble L.E., Kershaw Y.M., Wood S.A., Lightman S.L., Ingram C.D. Gonadal steroid modulation of stress-induced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin. Endocrinology 2006, 147:2423-2431.
68. McCarthy M.M., McDonald C.H., Brooks P.J., Goldman D. An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiology and Behavior 1996, 60:1209-1215.
69. Bale T.L., Davis A.M., Auger A.P., Dorsa D.M., McCarthy M.M. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. Journal of Neuroscience 2001, 21:2546-2552.
70. Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biological Psychiatry 2003, 54:1389-1398.
71. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience 2005, 25:11489-11493.
72. Olson B., Drutarosky M., Chow M., Hruby V., Stricker E., Verbalis J. Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats. Peptides 1991, 12:113-118.
73. Verbalis J.G., Blackburn R.E., Olson B.R., Stricker E.M. Central oxytocin inhibition of food and salt ingestion: a mechanism for intake regulation of solute homeostasis. Regulatory Peptides 1993, 45:149-154.
74. Sclafani A., Rinaman L., Vollmer R.R., Amico J.A. Oxytocin knockout mice demonstrate enhanced intake of sweet and nonsweet carbohydrate solutions. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2007, 292:R1828-R1833.
75. Swaab D.F., Purba J.S., Hofman M.A. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. The Journal of Clinical Endocrinology and Metabolism 1995, 80:573-579.
76. Vrang N., Larsen P.J., Kristensen P., Tang-Christensen M. Central administration of cocaine-amphetamine-regulated transcript activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 2000, 141:794-801.
77. Maruyama M., Matsumoto H., Fujisawa K., Kitada C., Hinuma S., Onda H., Fujino M., Inoue K. Imunocytochemical localization of prolactinreleasing peptide in the rat brain. Endocrinology 1999, 140:2326-2333.
78. Maruyama M., Matsumoto H., Fujisawa K., Noguchi J., Kitada C., Hinuma S., Onda H., Nishimura O., Fujino M., Higuchi T., Inoue K. Central administration of prolactin-releasing peptide stimulates oxytocin release in rats. Neuroscience Letters 1999, 276:193-196.
79. Olszewski P.K., Wirth M.M., Shaw T.J., Grace M.K., Billington C.J., Giraudo S.Q., Levine A.S. Role of a-MSH in the regulation of consummatory behavior: immunohistochemical evidence. American Journal of Physiology 2001, 281:R673-R680.
80. Bjkstrand E., Uvn-Moberg K. Central oxytocin increases food intake and daily weight gain in rats. Physiology & Behavior 1996, 59:947-952.
81. McMahon L.R., Wellman P.J. Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats. Pharmacology, Biochemistry, and Behavior 1997, 57:767-770.
82. Verbalis J.G., Blackburn R.E., Hoffman G.E., Stricker E.M. Establishing behavioral and physiological functions of central oxytocin: insights from studies of oxytocin and ingestive behaviors. Advances in Experimental Medicine and Biology 1995, 395:209-225.
83. Diaz-Cabiale Z., Narvaez J.A., Petersson M., Uvnas-Moberg K., Fuxe K. Oxytocin/alpha2-adrenoceptor interactions in feeding responses. Neuroendocrinology 2000, 71:209-218.
84. Maejima Y., Iwasaki Y., Yamahara Y., Kodaira M., Sedbazar U., Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging 2011, 3:1169-1177. (Albany NY).
85. Lawson E.A., Donoho D.A., Blum J.I., Meenaghan E.M., Misra M., Herzog D.B., Sluss P.M., Miller K.K., Klibanski A. Decreased nocturnal oxytocin levels in anorexia nervosa are associated with low bone mineral density and fat mass. The Journal of Clinical Psychiatry 2011, 72:1546-1551.
86. Chiodera P., Volpi R., Capretti L., Marchesi C., d'Amato L., De Ferri A., Bianconi L., Coiro V. Effect of estrogen or insulin-induced hypoglycemia on plasma oxytocin levels in bulimia and anorexia nervosa. Metabolism 1991, 40:1226-1230.
87. Frank G.K., Kaye W.H., Altemus M., Greeno C.G. CSF oxytocin and vasopressin levels after recovery from bulimia nervosa and anorexia nervosa, bulimic subtype. Biological Psychiatry 2000, 48:315-318.
88. Blackburn R.E., Stricker E.M., Verbalis J.G. Central oxytocin mediates inhibition of sodium appetite by naloxone in hypovolemic rats. Neuroendocrinology 1992, 56:255-263.
89. Blackburn R.E., Demko A.D., Hoffman G.E., Stricker E.M., Verbalis J.G. Central oxytocin inhibition of angiotensin-induced salt appetite in rats. American Journal of Physiology 1992, 263:R1347-R1353.
90. Puryear R., Rigatto K.V., Amico J.A., Morris M. Enhanced salt intake in oxytocin deficient mice. Experimental Neurology 2001, 171:323-328.
91. Blackburn R.E., Samson W.K., Fulton R.J., Stricker E.M., Verbalis J.G. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. American Journal of Physiology 1995, 269:R245-R251.
92. Rigatto K., Puryear R., Bernatova I., Morris M. Salt appetite and the renin-angiotensin system: effect of oxytocin deficiency. Hypertension 2003, 42:793-797.
93. Amico J.A., Morris M., Vollmer R.R. Mice deficient in oxytocin manifest increased saline consumption following overnight fluid deprivation. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2001, 281:R1368-R1373.
94. Vollmer R.R., Li X., Karam J.R., Amico J.A. Sodium ingestion in oxytocin knockout mice. Experimental Neurology 2006, 202:441-448.
95. Popik P., Vos P.E., van Ree J.M. Neurohypophyseal hormone receptors in the septum are implicated in social recognition in the rat. Behavioural Pharmacology 1992, 3:351-358.
96. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nature Genetics 2000, 25:284-288.
97. Choleris E., Gustafsson J.A., Korach K.S., Muglia L.J., Pfaff D.W., Ogawa S. An oestrogen dependent 4-gene micronet regulating social recognition: a study with oxytocin and estrogen receptor-a and -b knockout mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:6192-6197.
98. Ferguson J.N., Aldag J.M., Insel T.R., Young L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse. Journal of Neuroscience 2001, 2:8278-8285.
99. Choleris E., Little S.R., Mong J.A., Puram S.V., Langer R., Pfaff D.W. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4670-4675.
100. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochemical and Biophysical Research Communications 1993, 192:553-560.
101. Ogoshi M., Inoue K., Takei Y. Identification of a novel adrenomedullin gene family in teleost fish. Biochemical and Biophysical Research Communications 2003, 311:1072-1077.
102. Roh J., Chang C.L., Bhalla A., Klein C., Hsu S.Y. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. The Journal of Biological Chemistry 2004, 279:7264-7274.
103. Takei Y., Inoue K., Ogoshi M., Kawahara T., Bannai H., Miyano S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Letters 2004, 556:53-58.
104. Eguchi S., Hirata Y., Iwasaki H., Sato K., Watanabe T.X., Inui T., Nakajima K., Sakakibara S., Marumo F. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. Endocrinology 1994, 135:2454-2458.
105. Conner A.C., Hay D.L., Howitt S.G., Kilk K., Langel U., Wheatley M., Smith D.M., Poyner D.R. Interaction of calcitonin-gene-related peptide with its receptors. Biochemical Society Transactions 2002, 30:451-455.
106. Fujisawa Y., Nagai Y., Miyatake A., Takei Y., Miura K., Shoukouji T., Nishiyama A., Kimura S., Abe Y. Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. European Journal of Pharmacology 2004, 497:75-80.
107. Fujisawa Y., Nagai Y., Miyatake A., Miura K., Shokoji T., Nishiyama A., Kimura S., Abe Y. Roles of adrenomedullin 2 in regulating the cardiovascular and sympathetic nervous systems in conscious rats. American Journal of Physiology. Heart and Circulatory Physiology 2006, 290:H1120-H1127.
108. Saita M., Shimokawa A., Kunitake T., Kato K., Hanamori T., Kitamura K., Eto T., Kannan H. Central actions of adrenomedullin on cardiovascular parameters and sympathetic outflow in conscious rats. American Journal of Physiology 1998, 274:R979-R984.
109. Takahashi H., Watanabe T.X., Nishimura M., Nakanishi T., Sakamoto M., Yoshimura M., Komiyama Y., Masuda M., Murakami T. Centrally induced vasopressor and sympathetic responses to a novel endogenous peptide, adrenomedullin, in anesthetized rats. American Journal of Hypertension 1994, 7:478-482.
110. Taylor M.M., Bagley S.L., Samson W.K. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2005, 288:R919-R927.
111. Serino R., Ueta Y., Hara Y., Nomura M., Yamamoto Y., Shibuya I., Hattori Y., Kitamura K., Kangawa K., Russell J.A., Yamashita H. Centrally administered adrenomedullin increases plasma oxytocin level with induction of c-fos messenger ribonucleic acid in the paraventricular and supraoptic nuclei of the rat. Endocrinology 1999, 140:2334-2342.
112. Ueta Y., Serino R., Shibuya I., Kitamura K., Kangawa K., Russell J.A., Yamashita H. A physiological role for adrenomedullin in rats; a potent hypotensive peptide in the hypothalamo-neurohypophysial system. Experimental Physiology 2000, 85:163S-169S.
113. Hashimoto H., Hyodo S., Kawasaki M., Mera T., Chen L., Soya A., Saito T., Fujihara H., Higuchi T., Takei Y., Ueta Y. Centrally administered adrenomedullin 2 activates hypothalamic oxytocin-secreting neurons, causing elevated plasma oxytocin level in rats. American Journal of Physiology. Endocrinology and Metabolism 2005, 289:E753-E761.
114. Murphy T.C., Samson W.K. The novel vasoactive hormone, adrenomedullin, inhibits water drinking in the rat. Endocrinology 1995, 136:2459-2463.
115. Samson W.K., Murphy T.C. Adrenomedullin inhibits salt appetite. Endocrinology 1997, 138:613-616.
116. Taylor G.M., Meeran K., O'Shea D., Smith D.M., Ghatei M.A., Bloom S.R. Adrenomedullin inhibits feeding in the rat by a mechanism involving calcitonin gene-related peptide receptors. Endocrinology 1996, 137:3260-3264.
117. Yokoi H., Arima H., Murase T., Kondo K., Iwasaki Y., Oiso Y. Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats. Neuroscience Letters 1996, 216:65-67.
118. Hashimoto H., Hyodo S., Kawasaki M., Shibata M., Saito T., Suzuki H., Otsubo H., Yokoyama T., Fujihara H., Higuchi T., Takei Y., Ueta Y. Adrenomedullin 2 (AM2)/intermedin is a more potent activator of hypothalamic oxytocin-secreting neurons than AM possibly through an unidentified receptor in rats. Peptides 2007, 28:1104-1112.
119. Ogoshi M., Inoue K., Naruse K., Takei Y. Evolutionary history of the calcitonin gene-related peptide family in vertebrates revealed by comparative genomic analyses. Peptides 2006, 27:3154-3164.
120. Otsubo H., Hyodo S., Hashimoto H., Kawasaki M., Suzuki H., Saito T., Ohbuchi T., Yokoyama T., Fujihara H., Matsumoto T., Takei Y., Ueta Y. Centrally administered adrenomedullin 5 activates oxytocin-secreting neurons in the hypothalamus and elevates plasma oxytocin level in rats. The Journal of Endocrinology 2009, 202:237-247.
121. Ueta Y., Kitamura K., Isse T., Shibuya I., Kabashima N., Yamamoto S., Kangawa K., Matsuo H., Eto T., Yamashita H. Adrenomedullin-immunoreactive neurons in the paraventricular and supraoptic nuclei of the rat. Neuroscience Letters 1995, 202:37-40.
122. O'Dowd B.F., Heiber M., Chan A., Heng H.H., Tsui L.C., Kennedy J.L., Shi X., Petronis A., George S.R., Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993, 136:355-360.
123. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., Kawamata Y., Fukusumi S., Hinuma S., Kitada C., Kurokawa T., Onda H., Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications 1998, 251:471-476.
124. De Mota N., Lenkei Z., Llorens-Corte's C. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology 2000, 72:400-407.
125. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., Osmond D.H., George S.R., O'Dowd B.F. Characterization of apelin, the ligand for the APJ receptor. Journal of Neurochemistry 2000, 74:34-41.
126. De Mota N., Reaux-Le Goazigo A., El Messari S., Chartrel N., Roesch D., Dujardin C., Kordon C., Vaudry H., Moos F., Llorens-Cortes C. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10464-10469.
127. Reaux A., De Mota N., Skultetyova I., Lenkei Z., El Messari S., Gallatz K., Corvol P., Palkovits M., Llorens-Corte's C. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. Journal of Neurochemistry 2001, 77:1085-1096.
128. Reaux-Le Goazigo A., Morinville A., Burlet A., Llorens-Cortes C., Beaudet A. Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology 2004, 145:4392-4400.
129. Reaux A., Gallatz K., Palkovits M., Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 2002, 113:653-662.
130. Kawamata Y., Habata Y., Fukusumi S., Hosoya M., Fujii R., Hinuma S., Nishizawa N., Kitada C., Onda H., Nishimura O., Fujino M. Molecular properties of apelin: tissue distribution and receptor binding. Biochimica et Biophysica Acta 2001, 1538:162-171.
131. Medhurst A.D., Jennings C.A., Robbins M.J., Davis R.P., Ellis C., Winborn K.Y., Lawrie K.W., Hervieu G., Riley G., Bolaky J.E., Herrity N.C., Murdock P., Darker J.G. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. Journal of Neurochemistry 2003, 84:1162-1172.
132. O'Carroll A.M., Selby T.L., Palkovits M., Lolait S.J. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochimica et Biophysica Acta 2000, 1492:72-80.
133. Xi D., Kusano K., Gainer H. Quantitative analysis of oxytocin and vasopressin messenger ribonucleic acids in single magnocellular neurons isolated from supraoptic nucleus of rat hypothalamus. Endocrinology 1999, 140:4677-4682.
134. Brailoiu G.C., Dun S.L., Yang J., Ohsawa M., Chang J.K., Dun N.J. Apelin-immunoreactivity in the rat hypothalamus and pituitary. Neuroscience Letters 2002, 327:193-197.
135. Tobin V.A., Bull P.M., Arunachalam S., O'Carroll A.M., Ueta Y., Ludwig M. The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic peptide release. Endocrinology 2008, 149:6136-6145.
136. Bodineau L., Taveau C., Lê Quan Sang H.H., Osterstock G., Queguiner I., Moos F., Frugière A., Llorens-Cortes C. Data supporting a new physiological role for brain apelin in the regulation of hypothalamic oxytocin neurons in lactating rats. Endocrinology 2011, 152:3492-3503.
137. Moran T.H. Cholecystokinin and satiety: current perspectives. Nutrition 2000, 16:858-865.
138. Verbalis J.G., McCann M.J., McHale C.M., Stricker E.M. Oxytocin secretion in response to cholecystokinin and food: differentiation of nausea from satiety. Science 1986, 232:1417-1419.
139. Renaud L.P., Tang M., McCann M.J., Stricker E.M., Verbalis J.G. Cholecystokinin and gastric distension activate oxytocinergic cells in rat hypothalamus. American Journal of Physiology 1987, 253:R661-R665.
140. McCann M.J., Verbalis J.G., Stricker E.M. LiCl and CCK inhibit gastric emptying and feeding and stimulate OT secretion in rats. American Journal of Physiology 1989, 256:R463-R468.
141. Ueta Y., Kannan H., Higuchi T., Negoro H., Yamaguchi K., Yamashita H. Activation of gastric afferents increases noradrenaline release in the paraventricular nucleus and plasma oxytocin level. Journal of the Autonomic Nervous System 2000, 78:69-76.
142. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992, 41:1422-1428.
143. Kawano K., Hirashima T., Mori S., Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Research and Clinical Practice 1994, 24(Suppl.):S317-S320.
144. Funakoshi A., Miyasaka K., Shinozaki H., Masuda M., Kawanami T., Takata Y., Kono A. An animal model of congenital defect of gene expression of cholecystokinin (CCK)-A receptor. Biochemical and Biophysical Research Communications 1995, 210:787-796.
145. Hashimoto H., Onaka T., Kawasaki M., Chen L., Mera T., Soya A., Saito T., Fujihara H., Sei H., Morita Y., Ueta Y. Effects of cholecystokinin (CCK)-8 on hypothalamic oxytocin-secreting neurons in rats lacking CCK-A receptor. Autonomic Neuroscience: Basic & Clinical 2005, 121:16-25.
146. Verbalis J.G., McHale C.M., Gardiner T.W., Stricker E.M. Oxytocin and vasopressin secretion in response to stimuli producing learned taste aversions in rats. Behavioral Neuroscience 1986, 100:466-475.
147. McCann M.J., Verbalis J.G., Stricker E.M. Capsaicin pretreatment attenuates multiple responses to cholecystokinin in rats. Journal of the Autonomic Nervous System 1988, 23:265-272.
148. Luckman S.M., Hamamura M., Antonijevic I., Dye S., Leng G. Involvement of cholecystokinin receptor types in pathways controlling oxytocin secretion. British Journal of Pharmacology 1993, 110:378-384.
149. Raybould H.E., Gayton R.J., Dockray G.J. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. Journal of Neuroscience 1988, 8:3018-3024.
150. Rinaman L., Verbalis J.G., Stricker E.M., Hoffman G.E. Distribution and neurochemical phenotypes of caudal medullary neurons activated to express cFos following peripheral administration of cholecystokinin. The Journal of Comparative Neurology 1993, 338:475-490.
151. Kendrick K.M., Keverne E.B., Hinton M.R., Goode J.A. Cerebrospinal fluid and plasma concentrations of oxytocin and vasopressin during parturition and vaginocervical stimulation in the sheep. Brain Research Bulletin 1991, 26:803-807.
152. Crawley J.N., Schwaber J.S. Abolition of the behavioral effects of cholecystokinin following bilateral radiofrequency lesions of the parvocellular subdivision of the nucleus tractus solitarius. Brain Research 1984, 295:289-299.
153. Leng G., Brown C.H., Russel J.A. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Progress in Neurobiology 1999, 57:625-655.
154. Onaka T. Catecholaminergic mechanisms underlying neurohypophysial hormone responses to unconditioned or conditioned aversive stimuli in rats. Experimental Physiology 2000, 85S:101S-110S.
155. Ueta Y., Kannan H., Higuchi T., Negoro H., Yamashita H. CCK-8 excites oxytocin-secreting neurons in the paraventricular nucleus in rats: possible involvement of noradrenergic pathway. Brain Research Bulletin 1993, 32:453-459.
156. Zhu L., Onaka T. Involvement of medullary A2 noradrenergic neurons in the activation of oxytocin neurons after conditioned fear stimuli. The European Journal of Neuroscience 2002, 16:2186-2198.
157. Onaka T., Yamashita T., Liu X., Honda K., Saito T., Yagi K. Medullary A1 noradrenergic neurons may mediate oxytocin release after noxious stimuli. Neuroreport 2001, 12:2499-2502.
158. Olson B.R., Drutarosky M.D., Stricker E.M., Verbalis J.G. Oxytocin and oxytocin agonist administered centrally decrease food intake in rats. Peptides 1991, 12:113-118.
159. Olson B.R., Drutarosky M.D., Stricker E.M., Verbalis J.G. Brain oxytocinreceptor antagonism blunts the effects of anorexigenic treatments in rats: evidence for central oxytocin inhibition of food intake. Endocrinology 1991, 129:785-791.
160. Olson B.R., Drutarosky M.D., Stricker E.M., Vebalis J.G. Brain oxytocin receptors mediate corticotropin-releasing hormone-induced anorexia. American Journal of Physiology 1991, 260:R448-R452.
161. Gottsch M.L., Cunningham M.J., Smith J.T., Popa S.M., Acohido B.V., Crowley W.F., Seminara S., Clifton D.K., Steiner R.A. A role for kisspeptins in the regulation of gonadotrophin secretion in the mouse. Endocrinology 2004, 145:4073-4077.
162. Irwig M.S., Fraley G.S., Smith J.T., Acohido B.V., Popa S.M., Cunningham M.J., Gottsch M.L., Clifton D.K., Steiner R.A. Kisspeptin activation of gonadotrophin releasing hormone neurons and regulation of KiSS-1 mRNA in the male rat. Neuroendocrinology 2004, 80:264-272.
163. Messager S., Chatzidaki E.E., Ma D., Hendrick A.G., Zahn D., Dixon J., Thresher R.R., Malinge I., Lomet D., Carlton M.B., Colledge W.H., Caraty A., Aparicio S.A. Kisspeptin directly stimulates gonadotrophin-releasing hormone release via G protein-coupled receptor 54. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1761-1766.
164. Navarro V.M., Castellano J.M., Fernandez-Fernandez R., Tovar S., Roa J., Mayen A., Nogueiras R., Vazquez M.J., Barreiro M.L., Magni P., Aguilar E., Dieguez C., Pinilla L., Tena-Sempere M. Characterization of the potent luteinizing hormone releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology 2005, 146:156-163.
165. Shahab M., Mastronardi C., Seminara S.B., Crowley W.F., Ojeda S.R., Plant T.M. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:2129-2134.
166. Navarro V.M., Fernandez-Fernandez R., Castellano J.M., Roa J., Mayen A., Barreiro M.L., Gaytan F., Aguilar E., Pinilla L., Dieguez C., Tena-Sempere M. Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. The Journal of Physiology 2004, 561:379-386.
167. Ohtaki T., Shintani Y., Honda S., Matsumoto H., Hori A., Kanehashi K., Terao Y., Kumano S., Takatsu Y., Masuda Y., Ishibashi Y., Watanabe T., Asada M., Yamada T., Suenaga M., Kitada C., Usuki S., Kurokawa T., Onda H., Nishimura O., Fujino M. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001, 411:613-617.
168. Richard N., Galmiche G., Corvaisier S., Caraty A., Kottler M.L. KiSS-1 and GPR54 genes are co-expressed in rat gonadotrophs and differentially regulated in vivo by oestradiol and gonadotrophin-releasing hormone. Journal of Neuroendocrinology 2008, 2008(20):381-393.
169. Gaytán F., Gaytán M., Castellano J.M., Romero M., Roa J., Aparicio B., Garrido N., Sánchez-Criado J.E., Millar R.P., Pellicer A., Fraser H.M., Tena-Sempere M. KiSS-1 in the mammalian ovary: distribution of kisspeptin in human and marmoset and alterations in KiSS-1 mRNA levels in a rat model of ovulatory dysfunction. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E520-E531.
170. Muir A.I., Chamberlain L., Elshourbagy N.A., Michalovich D., Moore D.J., Calamari A., Szekeres P.G., Sarau H.M., Chambers J.K., Murdock P., Steplewski K., Shabon U., Miller J.E., Middleton S.E., Darker J.G., Larminie C.G., Wilson S., Bergsma D.J., Emson P., Faull R., Philpott K.L., Harrison D. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1.C. The Journal of Biological Chemistry 2001, 276:28969-28975.
171. Horikoshi Y., Matsumoto H., Takatsu Y., Ohtaki T., Kitada C., Usuki S., Fujino M. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. Journal of Clinical Endocrinology and Metabolism 2003, 88:914-919.
172. Rometo A.M., Krajewski S.J., Voytko M.L., Rance N.E. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. Journal of Clinical Endocrinology and Metabolism 2007, 92:2744-2750.
173. Kotani M., Detheux M., Vandenbogaerde A., Communi D., Vanderwinden J.M., Le Poul E., Bre'zillon S., Tyldesley R., Suarez-Huerta N., Vandeput F., Blanpain C., Schiffmann S.N., Vassart G., Parmentier M. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. The Journal of Biological Chemistry 2001, 276:34631-34636.
174. Ten S.C., Gu S.Y., Niu Y.F., An X.F., Yan M., He M. Central administration of kisspeptin-10 inhibits water and sodium excretion of anesthetized male rats and the involvement of arginine vasopressin. Endocrine Research 2010, 35:128-136.
175. Scott V., Brown C.H. Kisspeptin activation of supraoptic nucleus neurons in vivo. Endocrinology 2011, 152:3862-3870.
176. Oh-I S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., Eguchi H., Yamamoto M., Imaki T., Hashimoto K., Tsuchiya T., Monden T., Horiguchi K., Yamada M., Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006, 443:709-712.
177. Foo K., Brismar H., Broberger C. Distribution and neuropeptide coex-istence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008, 156:563-579.
178. Kohno D., Nakata M., Maejima Y., Shimizu H., Sedbazar U., Yoshida N., Dezaki K., Onaka T., Mori M., Yada T. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008, 149:1295-1301.
179. Brailoiu G.C., Dun S.L., Brailoiu E., Inan S., Yang J., Chang J.K., Dun N.J. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007, 148:5088-5094.
180. Yosten G.L., Samson W.K. The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2010, 298:R1642-R1647.
181. Maejima Y., Sedbazar U., Suyama S., Kohno D., Onaka T., Takano E., Yoshida N., Koike M., Uchiyama Y., Fujiwara K., Yashiro T., Horvath T.L., Dietrich M.O., Tanaka S., Dezaki K., Oh-I S., Hashimoto K., Shimizu H., Nakata M., Mori M., Yada T. Nesfatin-1 regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metabolism 2009, 10:355-365.
182. Atsuchi K., Asakawa A., Ushikai M., Ataka K., Tsai M., Koyama K., Sato Y., Kato I., Fujimiya M., Inui A. Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. Neuroreport 2010, 21:1008-1011.
183. Hinuma S., Habata Y., Fujii R., Hosoya M., Fukusumi S., Kitada C., Masuo Y., Asano T., Matsumoto H., Sekiguchi M., Kurokawa T., Nishimura O., Onda H., Fujino M. A prolactin-releasing peptide in the brain. Nature 1998, 393:272-276.
184. Matsumoto H., Noguchi J., Horikoshi Y., Kawamata Y., Kitada C., Hinuma S., Onda H., Nishimura O., Fujino M. Stimulation of prolactin release by prolactin-releasing peptide in rats. Biochemical and Biophysical Research Communications 1999, 259:321-324.
185. Tokita R., Nakata T., Katsumata H., Konishi S., Onodera H., Imaki J., Minami S. Prolactin secretion in response to prolactin-releasing peptide and the expression of the prolactin-releasing peptide gene in the medulla oblongata are estrogen dependent in rats. Neuroscience Letters 1999, 276:103-106.
186. Havel P.J., Hahn T.M., Sindelar D.K., Baskin D.G., Dallman M.F., Weigle D.S., Schwartz M.W. Effect of streptozotocin-induced diabetes and insulin treatment on hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000, 49:244-252.
187. Jarry H., Heuer H., Schomburg L., Bauer K. Prolactin-releasing peptide do not stimulate prolactin release in vivo. Neuroendocrinology 2000, 71:262-267.
188. Samson W.K., Resch Z.T., Murphy T.C., Chang J.K. Gender-biased activity of the novel prolactin releasing peptide. Comparison with thyrotropin releasing hormone reveals only pharmacologic effects. Endocrine 1998, 9:289-291.
189. Sakamoto T., Fujimoto M., Ando M. Fishy tales of prolactin-releasing peptide. International Review of Cytology 2003, 225:91-130.
190. Taylor M.M., Samson W.K. Prolactin-releasing peptide: RF-amide peptide. Cellular and Molecular Life Sciences 2001, 58:1206-1215.
191. Minami S., Nakata T., Tokita R., Onodera H., Ibata Y. Cellular localization of prolactin-releasing peptide messenger RNA in the rat brain. Neuroscience Letters 1999, 266:73-76.
192. Chen C.T., Dun S.L., Chang J.K. Prolactin-releasing peptide im- munoreactivity in A1 and A2 noradrenergic neurons of the rat medulla. Brain Research 1999, 822:276-279.
193. Roland B.L., Sutton S.W., Wilson S.J., Luo L., Pyati J., Huvar R., Erlander M.G., Lovenberg T.W. Anatomical distribution of prolactin-releasing peptide and its receptor suggests additional functions in the central nervous system and periphery. Endocrinology 1999, 140:5736-5745.
194. Ibata Y., Iijima N., Kataoka Y., Kakihara K., Tanaka M., Hosoya M., Hinuma S. Morphological survey of prolactin-releasing peptide and its receptor with special reference to their functional roles in the brain. Neuroscience Research 2000, 38:223-230.
195. Matsumoto H., Maruyama M., Noguchi J., Horikoshi Y., Fujisawa K., Kitada C., Hinuma S., Onda H., Nishimura O., Inoue K., Fujino M. Stimulation of corticotropin-releasing hormone-mediated adrenocorticotropin secretion by central administration of prolactin-releasing peptide in rats. Neuroscience Letters 2000, 285:234-238.
196. Maruyama M., Matsumoto H., Fujisawa K., Noguchi J., Kitada C., Fujino M., Inoue K. Prolactin-releasing peptide as a novel stress mediator in the central nervous system. Endocrinology 2001, 142:2032-2038.
197. Zhu L., Onaka T. Facilitative role of prolactin-releasing peptide neurons in oxytocin cell activation after conditioned fear stimuli. Neuroscience 2003, 118:1045-1053.
198. Lawrence C.B., Ellacott K.L., Luckman S.M. PRL-releasing peptide reduces food intake and may mediate satiety signaling. Endocrinology 2000, 143:360-367.
199. Bechtold D.A., Luckman S.M. Prolactin-releasing peptide mediates CCK-induced satiety in mice. Endocrinology 2006, 147:4723-4729.
200. Mera T., Fujihara H., Kawasaki M., Hashimoto H., Saito T., Shibata M., Saito J., Oka T., Tsuji S., Onaka T., Ueta Y. Prolactin-releasing peptide is a potent mediator of stress responses in the brain through the hypothalamic paraventricular nucleus. Neuroscience 2006, 6141:1069-1086.
201. Lawrence C.B., Celsi F., Brennand J., Luckman S.M. Alternative role for prolactin-releasing peptide in the regulation of food intake. Nature Neuroscience 2000, 3:645-646.
202. Seal L.J., Small C.J., Dhillo W.S., Stanley S.A., Abbott C.R., Ghatei M.A., Bloom S.R. PRL-releasing peptide inhibits food intake in male rats via the dorsomedial hypothalamic nucleus and not the paraventricular hypothalamic nucleus. Endocrinology 2001, 142:4236-4243.
203. Ellacott K.L., Lawrence C.B., Rothwell N.J., Luckman S.M. PRL-releasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology 2002, 143:368-374.
204. Lawrence C.B., Liu Y.L., Stock M.J., Luckman S.M. Anorectic actions of prolactin-releasing peptide are mediated by corticotropin-releasing hormone receptors. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2004, 286:101-107.
205. Gu W., Geddes B.J., Zhang C., Foley K.P., Stricker-Krongrad A. The prolactin-releasing peptide receptor (GPR 10) regulates body weight homeostasis in mice. Journal of Molecular Neuroscience 2003, 22:93-103.
206. Kaewwongse M., Takayanagi Y., Onaka T. Effects of RFamide-related peptide (RFRP)-1 and RFRP-3 on oxytocin release and anxiety-related behaviour in rats. Journal of Neuroendocrinology 2011, 23:20-27.
207. Chey W.Y., Chang T. Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology 2001, 1:320-335.
208. Li Y., Wu X., Yao H., Owyang C. Secretin activates vagal primary afferent neurons in the rat: evidence from electrophysiological and immunohistochemical studies. American Journal of Physiology. Gastrointestinal and Liver Physiology 2005, 289:G745-G752.
209. Yang H., Wang L., Wu S.V., Tay J., Goulet M., Boismenu R., Czimmer J., Wang Y., Wu S., Ao Y., Taché Y. Peripheral secretin-induced Fos expression in the rat brain is largely vagal dependent. Neuroscience 2004, 128:131-141.
210. Welch M.G., Keune J.D., Welch-Horan T.B., Anwar N., Anwar M., Ludwig R.J., Ruggiero D.A. Secretin: hypothalamic distribution and hypothesized neuroregulatory role in autism. Cellular and Molecular Neurobiology 2004, 24:219-241.
211. Fuxe K., Andersson K., Hokfelt T., Mutt V., Ferland L., Agnati L.F., Ganten D., Said S., Eneroth P., Gustafsson J.A. Localization and possible function of peptidergic neurons and their interactions with central catecholamine neurons, and the central actions of gut hormones. Federation Proceedings 1979, 38:2333-2340.
212. Itoh N., Furuya T., Ozaki K., Ohta M., Kawasaki T. The secretin precursor gene. Structure of the coding region and expression in the brain. The Journal of Biological Chemistry 1991, 266:12595-12598.
213. Samson W.K., Lumpkin M.D., McCann S.M. Presence and possible site of action of secretin in the rat pituitary and hypothalamus. Life Sciences 1984, 34:155-163.
214. Goulet M., Shiromani P.J., Ware C.M., Strong R.A., Boismenu R., Rusche J.R. A secretin iv infusion activates gene expression in the central amygdala of rats. Neuroscience 2003, 118:881-888.
215. Chu J.Y., Yung W.H., Chow B.K. Endogenous release of secretin from the hypothalamus. Annals of the New York Academy of Sciences 2006, 1070:196-200.
216. Nishijima I., Yamagata T., Spencer C.M., Weeber E.J., Alekseyenko O., Sweatt J.D., Momoi M.Y., Ito M., Armstrong D.L., Nelson D.L., Paylor R., Bradley A. Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior. Human Molecular Genetics 2006, 15:3241-3250.
217. Horvath K., Stefanatos G., Sokolski K.N., Wachtel R., Nabors L., Tildon J.T. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians 1998, 9:9-15.
218. Williams K.W., Wray J.J., Wheeler D.M. Intravenous secretin for autism spectrum disorder. Cochrane Database of Systematic Reviews 2005, 3:CD003495.
219. Welch M.G., Anwar M., Chang C.Y., Gross K.J., Ruggiero D.A., Tamir H., Gershon M.D. Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons. Neurogastroenterology and Motility 2010, 22:654-e202.
220. Bruhn T.O., Sutton S.W., Plotsky P.M., Vale W.W. Central administration of corticotropin-releasing factor modulates oxytocin secretion in the rat. Endocrinology 1986, 119:1558-1563.
221. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
222. Zueco J.A., Esquifino A.I., Chowen J.A., Alvarez E., Castrillón P.O., Blázquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36) amide on vasopressin and oxytocin release. Journal of Neurochemistry 1999, 72:10-16.
223. Bojanowska E., Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regulatory Peptides 2000, 91:75-81.
224. Caquineau C., Leng G., Guan X.M., Jiang M., Van der Ploeg L., Douglas A.J. Effects of alpha-melanocyte-stimulating hormone on magnocellular oxytocin neurones and their activation at intromission in male rats. Journal of Neuroendocrinology 2006, 18:685-691.
225. Sabatier N., Caquineau C., Dayanithi G., Bull P., Douglas A.J., Guan X.M., Jiang M., Van der Ploeg L., Leng G. Alpha-melanocyte-stimulating hormone stimulates oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. The Journal of Neuroscience 2003, 23:10351-10358.
226. Ozaki Y., Onaka T., Nakazato M., Saito J., Kanemoto K., Matsumoto T., Ueta Y. Centrally administered neuromedin U activates neurosecretion and induction of c-fos messenger ribonucleic acid in the paraventricular and supraoptic nuclei of rat. Endocrinology 2002, 143:4320-4329.
227. Coombes J.E., Robinson I.C., Antoni F.A., Russell J.A. Release of oxytocin into blood and into cerebrospinal fluid induced by naloxone in anaesthetized morphine-dependent rats: the role of the paraventricular nucleus. Journal of Neuroendocrinology 1991, 3:551-561.
228. Douglas A.J., Neumann I., Meeren H.K., Leng G., Johnstone L.E., Munro G., Russell J.A. Central endogenous opioid inhibition of supraoptic oxytocin neurons in pregnant rats. The Journal of Neuroscience 1995, 15:5049-5057.
229. Ciosek J., Izdebska K. Thyrotropin-releasing hormone modulates vasopressin and oxytocin synthesis and release from the hypothalamo-neurohypophysial system of different age male rats. Journal of Physiology and Pharmacology 2009, 60:63-70.
230. Bardrum B., Ottesen B., Fahrenkrug J., Fuchs A.R. Release of oxytocin and vasopressin by intracerebroventricular vasoactive intestinal polypeptide. Endocrinology 1988, 123:2249-2254.